Dr. Uy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 314-454-8304Fax+1 314-454-5902
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2003 - 2007
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2001 - 2003
- Washington University in St. Louis School of MedicineClass of 2001
Certifications & Licensure
- IL State Medical License 2020 - 2026
- MO State Medical License 2002 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Clinical Trials
- Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia Start of enrollment: 1999 Apr 01
- AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia Start of enrollment: 2007 Jul 01
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
- Join now to see all
Publications & Presentations
PubMed
- 13 citationsGilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of.Mark J Levis, Mehdi Hamadani, Brent Logan, Richard J Jones, Anurag K Singh
Journal of Clinical Oncology. 2024-05-20 - 191 citationsFlotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt
Blood. 2021-02-11 - 56 citationsComplex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.Krzysztof Mrózek, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Andrew J. Carroll, Christopher J. Walker
Leukemia. 2019-02-08
Journal Articles
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLDaniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
- Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell TransplantationM A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature
Abstracts/Posters
- CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell DeathGeoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Int...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- You Make the Call: How Would You Treat This Transplant-Ineligible Patient with Ph+ ALL?September 30th, 2021
- MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual MeetingDecember 11th, 2019
- GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AMLApril 23rd, 2019
- Join now to see all
Grant Support
- Targeting Leukemia Stromal Interactions In AMLNational Cancer Institute2009–2011
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: